AVITA Medical Shares Rose 329% In A Year, Medicare Resets Its Billing Codes Next
TITLE: AVITA Medical Shares Surge 329 Percent Over Past Year as New Medicare Billing Rules Approach
AVITA Medical, Inc., which trades on the NASDAQ under the symbol RCEL, has delivered an exceptional performance for its shareholders over the last twelve months. The medical technology company has seen its stock price climb by 329 percent during this one-year period, marking it as a significant gainer in the healthcare sector. This massive appreciation in market value comes as the firm continues to expand the reach of its innovative wound care technology and prepares for upcoming changes in federal reimbursement policies.
Revenue Growth and the Skin Cell Product
The company recently provided an update on its financial health, reporting that its revenue for the third quarter increased by 53 percent. This substantial growth highlights the increasing commercial adoption of its primary medical offering. AVITA Medical markets a specialized system that assists in the treatment of burn victims. The technology works by taking a patient’s own skin cells and spraying them directly onto a wound to facilitate healing. By using the individual’s own biological material, the product offers a unique approach to skin regeneration and injury recovery.
Market analysts have responded to these financial results and the company’s technological progress with a positive outlook. Currently, investment experts maintain a Buy rating on AVITA Medical shares. These analysts have established a 12-month price target of $20 for the stock, suggesting that they anticipate further upward movement in the company’s valuation despite the triple-digit gains already recorded over the past year. The combination of 53 percent revenue growth and a specialized niche in the burn care market has positioned the firm as a notable player for those tracking medical innovations.
Medicare Resets Billing Codes
A major shift in the regulatory and financial landscape for the company is scheduled to take place at the start of the new year. On Jan. 1, the federal Medicare program will implement a change to its reimbursement framework that could affect how the company’s treatments are funded. Specifically, Medicare is moving to replace its current system of regional billing rates. This transition is part of a broader effort to reset the billing codes associated with these types of medical procedures.
The move away from localized or regional rates toward a different billing structure represents a pivotal moment for
Source: seekingalpha.com · 2026-11-14